Abstract: A novel method and compositions for the local treatment of Meniere's disease, tinnitus and hearing loss are described. The treatment is based on the administration of a therapeutically effective amount of a prostaglandin of the F-type to the inner ear. The treatment can be either continuous or intermittent and may involve the use of pumps, gels, or slow release drug inserts.

Abstract: The invention is related to a novel method and compositions for the treatment or alleviation of tinnitus. The compositions which are to be administered locally into the middle ear cavity, or orally, contain a therapeutically effective and physiologically acceptable amount of lithium. The treatment may be continuous or intermittent.

Abstract: The use of a prostaglandin A2 derivative, and prodrugs of the compound, for the manufacture of a medicament for the treatment and/or alleviation of psoriasis is presented, as well as a method of treatment, involving the topical application of such prostaglandins. Compositions containing a therapeutically active, and physiologically acceptable amount of the above compound or derivatives thereof, as such or in the form of a prodrug, in a suitable vehicle are also described. Importantly, the derivatives can be applied in therapeutically active amounts without or with only minimal side effects, such as hyperemia, irritation or pain.

Abstract: Novel methods and compositions for the local treatment of Meniere's disease, tinnitus and hearing loss employ a therapeutically effective amount of a prostaglandin of the F-type to the inner ear. The treatment can be either continuous or intermittent and may involve the use of pumps, gels, or slow release drug inserts.

Abstract: Prostaglandin-induced increased pigmentation of the iris can be avoided, or significantly reduced, when using a selective EP2 prostanoid receptor agonist in combination with an alpha-adrenergic agonist. Methods and compositions for the treatment of glaucoma and ocular hypertension are described.

Abstract: A novel method and compositions for the local treatment of Meniere's disease, tinnitus and hearing loss are described. The treatment is based on the administration of a therapeutically effective amount of a prostaglandin of the F-type to the inner ear. The treatment can be either continuous or intermittent and may invlove the use of pumps, gels, or slow release drug inserts.

Abstract: A selective EP2 or EP4 prostanoid receptor agonist can be used to treat female sexual dysfunction. Salts and esters of the agonists can also be used. Formulations comprising such agonists, salts, or esters can be in the form of a cream, gel, ointment, or solid, useful for topical administration.

Abstract: This invention is related to a method whereby scar formation in the drainage fistula and subconjunctival bleb created during and after glaucoma surgery using a prostaglandin subtype A or J.

Abstract: Compositions and methods for treatment of impotence or erectile dysfunction employ prostaglandins that are selective EP2 or EP4 prostanoid receptor agonists. The compositions can be formulated for intracavernous injection, or for transurethral or transdermal application.

Abstract: Molecular cloning and expression of a prostaglandin F2&agr; receptor which is linked to the signal transduction pathways via guanine nucleotide binding regulatory (G) proteins and measured by, for example, cAMP, IP3 or intracellular calcium. By constructing cell lines that express a prostaglandin F2&agr; receptor, the affinities and efficacies of agonist and antagonist drugs with the receptor can be assessed. A recombinant DNA construct includes a vector and a DNA fragment encoding a prostaglandin F2&agr; receptor. A host cell is transformed with a recombinant DNA construct, so that the DNA fragment is expressed and a prostaglandin F2&agr; receptor is produced. Suitable host systems include eukaryotic and prokaryotic cells, especially mamalian cells such as rat or human. Additionally, for diagnostic purposes, antibodies to a prostaglandin F2&agr; receptor can be prepared by producing all or a portion of the receptor protein and injecting these into various types of mammals.

Abstract: Methods for topical treatment of psoriasis are disclosed comprising applying to the skin a composition comprising an effective amount of a therapeutically active and physiologically acceptable prostaglandin A.sub.2, prostaglandin J, derivative of prostaglandin A.sub.2, derivative of prostaglandin J, an alkyl ester of prostaglandin A having 1-10 carbons in the alkyl group, or a benzyl ester of prostaglandin A, in a vehicle for topical application. Methods for inhibiting an increased proliferation of cell growth associated with psoriasis in epidermis are further disclosed comprising topically applying to the epidermis an effective amount of a therapeutically active and physiologically acceptable prostaglandin A, prostaglandin J, derivative of prostaglandin A or derivative of prostaglandin J, in a vehicle for topical application.

Abstract: Method and means for delivery of drugs to the optic nerve head and the region surrounding it which comprises contacting the surface of the eye with an effective amount of a drug for treatment of said nerve head and a physiologically acceptable prostaglandin or prostaglandin derivative for enhancing delivery of the drug to the nerve head, in an opththalmologically acceptable carrier.

Abstract: The present invention is related to the use of thiol-binding prostaglandins or prostaglandin-like substances containing alpha beta unsaturated ketone, esp. Prostaglandins of type A or J and derivatives or analogues thereof, for the preparation of ophthalmically compatible compositions for the prevention of cataracts.

Abstract: The present invention relates to a method for treatment or prevention of secondary cataract, comprising contacting the surface of the eye with an effective amount of a therapeutically active and physiologically acceptable prostaglandin comprising a prostaglandin A, a prostaglandin J, a derivative of prostaglandin A or a derivative of prostaglandin J.

Abstract: Molecular cloning and expression of a prostaglandin F2.alpha. receptor which is linked to the signal transduction pathways via guanine nucleotide binding regulatory (G) proteins and measured by, for example, cAMP, IP.sub.3 or intracellular calcium. By constructing cell lines that express a prostaglandin F2.alpha., receptor, the affinities and efficacies of agonist and antagonist drugs with the receptor can be assessed. A recombinant DNA construct includes a vector and a DNA fragment encoding a prostaglandin F2.alpha. receptor. A host cell is transformed with a recombinant DNA construct, so that the DNA fragment is expressed and a prostaglandin F2.alpha., receptor is produced. Suitable host systems include eukaryotic and prokaryotic cells, especially mamalian cells such as rat or human. Additionally, for diagnostic purposes, antibodies to a prostaglandin F2.alpha. receptor can be prepared by producing all or a portion of the receptor protein and injecting these into various types of mammals.

Abstract: The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE.sub.2, which are modified to contain a ring structure in the omega chain. The invention relates also to pharmaceutical compositions containing an active amount of these derivatives.

Abstract: The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE.sub.2, which are modified to contain a ring structure in the omega chain. The invention relates also to pharmaceutical compositions containing an active amount of these derivatives.